本文へ移動
電子書籍・電子雑誌Tropical medicine and health
巻号44
Human anti...

Human antibody response to dengue virus : implications for dengue vaccine design

記事を表すアイコン
表紙は所蔵館によって異なることがあります ヘルプページへのリンク

Human antibody response to dengue virus : implications for dengue vaccine design

国立国会図書館請求記号
Z1-286
国立国会図書館書誌ID
10233086
国立国会図書館永続的識別子
info:ndljp/pid/10233086
資料種別
記事
著者
Meng Ling Moiほか
出版者
Springer Nature
出版年
2016-03-14
資料形態
デジタル
掲載誌名
Tropical medicine and health 44(1)
掲載ページ
-
詳細を見る

国立国会図書館での利用に関する注記

本資料は、掲載誌(URI)等のリンク先にある電子書籍・電子雑誌の提供元Webサイトなどから、本文を自由に閲覧できる場合があります。

資料詳細

要約等:

Dengue, a global health threat, is a leading cause of morbidity and mortality in most tropical and subtropical countries. Dengue can range from asympt...

全国の図書館の所蔵

国立国会図書館以外の全国の図書館の所蔵状況を表示します。

所蔵のある図書館から取寄せることが可能かなど、資料の利用方法は、ご自身が利用されるお近くの図書館へご相談ください

その他

  • CiNii Research

    検索サービス
    デジタル
    連携先のサイトで、CiNii Researchが連携している機関・データベースの所蔵状況を確認できます。
  • CiNii Research

    検索サービス
    連携先のサイトで、CiNii Researchが連携している機関・データベースの所蔵状況を確認できます。

書誌情報

この資料の詳細や典拠(同じ主題の資料を指すキーワード、著者名)等を確認できます。

デジタル

資料種別
記事
著者・編者
Meng Ling Moi
Tomohiko Takasaki
Ichiro Kurane
出版年月日等
2016-03-14
出版年(W3CDTF)
2016-03-14
タイトル(掲載誌)
Tropical medicine and health
巻号年月日等(掲載誌)
44(1)
掲載巻
44(1)
ISSN(掲載誌)
1349-4147
ISSN-L(掲載誌)
1348-8945
本文の言語コード
eng
国立国会図書館永続的識別子
info:ndljp/pid/10233086
コレクション(共通)
コレクション(障害者向け資料:レベル1)
コレクション(個別)
国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他
収集根拠
オンライン資料収集制度
受理日(W3CDTF)
2016-12-28T13:40:57+09:00
保存日(W3CDTF)
2016-12-26
記録形式(IMT)
application/pdf
オンライン閲覧公開範囲
国立国会図書館内限定公開
デジタル化資料送信
図書館・個人送信対象外
遠隔複写可否(NDL)
掲載誌(国立国会図書館永続的識別子)
info:ndljp/pid/10233085
連携機関・データベース
国立国会図書館 : 国立国会図書館デジタルコレクション

デジタル

コレクション(個別)
国立国会図書館デジタルコレクション > デジタル化資料 > 雑誌
オンライン閲覧公開範囲
国立国会図書館内限定公開
デジタル化資料送信
図書館・個人送信対象
遠隔複写可否(NDL)
所蔵機関
国立国会図書館
請求記号
Z1-286
掲載誌(国立国会図書館永続的識別子)
info:ndljp/pid/12118332
連携機関・データベース
国立国会図書館 : 国立国会図書館雑誌記事索引
書誌ID(NDLBibID)
10233086
整理区分コード
632

デジタル

要約等
Dengue, a global health threat, is a leading cause of morbidity and mortality in most tropical and subtropical countries. Dengue can range from asymptomatic, relatively mild dengue fever to severe and life-threatening dengue hemorrhagic fever. Disease severity and outcome is largely associated with the host immune response. Several candidate vaccines in clinical trials appear promising as effective measures for dengue disease control. Vaccine development has been hampered by safety and efficacy issues, driven by a lack of understanding of the host immune response. This review focuses on recent research findings on the dengue host immune response, particularly in humans, and the relevance of these findings to challenges in vaccine development.
Tropical Medicine and Health, 44, 1; 2016
オンライン閲覧公開範囲
インターネット公開
著作権情報
c Moi et al 2016
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
参照
Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Serological evidence for the co-circulation of multiple dengue virus serotypes in Singapore
Detection of Higher Levels of Dengue Viremia Using FcγR-Expressing BHK-21 Cells Than FcγR-Negative Cells in Secondary Infection but Not in Primary Infection
Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing FcγRIIA
Anti-dengue virus envelope protein domain III IgG ELISA among infants with primary dengue virus infections
Impaired T Cell Proliferation in Acute Dengue Infection
Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection
RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND
Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection.
Comparison of Plaque- and Enzyme-Linked Immunospot-Based Assays To Measure the Neutralizing Activities of Monoclonal Antibodies Specific to Domain III of Dengue Virus Envelope Protein
Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes
Autochthonous Dengue Fever, Tokyo, Japan, 2014
Characteristic of Dengue Disease in Taiwan: 2002–2007
Autochthonous dengue fever in Croatia, August–September 2010
The global distribution and burden of dengue
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection
Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera
Antibody Responses to Asian and American Genotypes of Dengue 2 Virus in Immunized Mice
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine
A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells
High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection
Autochthonous case of dengue in France, October 2013
Discrepancy in Dengue Virus Neutralizing Antibody Titers between Plaque Reduction Neutralizing Tests with Fcγ Receptor (FcγR)-Negative and FcγR-Expressing BHK-21 Cells
Spatial and Temporal Circulation of Dengue Virus Serotypes: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever
Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants
Research on Dengue during World War II
Dengue Virus (DV) Enhancing Antibody Activity in Preillness Plasma Does Not Predict Subsequent Disease Severity or Viremia in Secondary DV Infection
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Differing Influences of Virus Burden and Immune Activation on Disease Severity in Secondary Dengue‐3 Virus Infections
Relationship of Preexisting Dengue Virus (DV) Neutralizing Antibody Levels to Viremia and Severity of Disease in a Prospective Cohort Study of DV Infection in Thailand
A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996.
The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
Difference between the Abilities of Human Fcγ Receptor-Expressing CV-1 Cells To Neutralize American and Asian Genotypes of Dengue Virus 2
Antibody-Dependent Enhancement of Dengue Virus Growth in Human Monocytes as a Risk Factor for Dengue Hemorrhagic Fever
T-cell Responses to Dengue Virus in Humans
連携機関・データベース
国立情報学研究所 : CiNii Research
提供元機関・データベース
学術機関リポジトリデータベース
雑誌記事索引データベース
Crossref
CiNii Articles
科学研究費助成事業データベース
書誌ID(NDLBibID)
10233086
NII論文ID
120006987654